CONCLUSIONS: The design of VBID initiatives in MS can inform outcomes and contracting strategies for manufacturers of MS therapies.

PND58
INTERCONNECTED HTA MAP FOR ALZHEIMER’S DISEASE – ANALYSIS OF DIVERGENCE AND COLLABORATION PATTERNS
Andreyev M1, Van Engen A2, Wiebinga C3, Zorzi G4, Mark R5
1Quintiles Global Consulting, Hoofddorp, The Netherlands; 2NL AC, Zurich, Switzerland
OBJECTIVES: To gain insights into stakeholders of Alzheimer’s disease and to reveal the diverse influences on reimbursement decisions in the interconnected HTA universe. METHODS: Eighty-four reports published by twenty-two Health Technology Assessment (HTA) agencies between 2000 and 2012 were identified to evaluate treatments for Alzheimer’s disease (fifty-eight of them assessed pharmaceuticals). Data extracted from those reports was supplemented with published information from other sources and divided into data categories (agencies, institutions, assessments, and people). Multiple attributes such as location, affiliation, type of research, methodology, technology, degree of influence, type of influence were assigned to each category and to connections between them. The visual analysis software and social networking analysis techniques were applied to this complex and densely interconnected dataset to observe the engagement and influence of various actors in reimbursement decisions. RESULTS: The visual analysis enabled to reveal commonalities and differences of approaches in evaluating Alzheimer’s treatments between agencies (decisions vs patient population, decision drivers). It also allowed identifying patterns of collaboration on specific areas where agencies were referring to each other, referring to the same sources such as Cochrane reviews, European Collaboration Initiatives (Alzheimer Europe, European Federation of Neurological Societies, European Medicines Agency Guideline), professional association guidelines (Alzheimer disease association, American College of Physicians). CONCLUSIONS: Alzheimer disease association, American College of Physicians.

PND59
TREATMENT, COMPLIANCE AND RELAPSE SEVERITY: USING COMPARATIVE EFFECTIVENESS RESEARCH TO GUIDE THE DESIGN OF OUTCOMES BASED CONTRACTING IN THE TREATMENT OF MULTIPLE SCLEROSIS
Lage MJ1, Carroll CA2
1Truven Health Analytics, Indianapolis, IN, USA; 2Truven Health Analytics, Kansas City, MO, USA
OBJECTIVES: To assess the utility of comparative effectiveness research in guiding the development of outcome based contracts. METHODS: The E3 InVison database was utilized to identify continuously enrolled patients between 18 and 64 years of age with 2 diagnoses of multiple sclerosis (MS) (ICD-9-CM of 340.xx). Receipt of a disease modifying therapy (DMT), with first such date was identified as the index date. Severe relapse was defined as either 1) a patient hospitalized with a diagnosis of MS in the post-period or a patient receiving a claim of an outpatient visit with a diagnosis of MS in the post-period. Univariate statistics (Adjusted R Square) were used to compare baseline patient characteristics. The probability of relapse was assessed using logistic controlling for patient characteristics (age, sex, region of residence, and insurance product), intent-to-treat, disease modifying therapy, type of chemotherapy, age, sex, race, ethnicity, Charlson index, medical ADL, prior relapse, and medical possession ratio (MPR). Differences in charges between the three groups were assessed using a generalized linear model with gamma distribution and log-link. RESULTS: A total of 2302 continuously enrolled patients met study criteria between the time frame of January 1, 2007 through March 31, 2010. Fourteen percent (34.5%, n = 333) and 13.79% of patients experienced a severe relapse requiring hospitalization and/or outpatient IV Methylprednisolone use, respectively. Univariate statistics revealed differences across groups with individuals with higher pre-period Charlson Index (p < 0.001), higher pre-period Medical ADL limitation proxy (p < 0.001) and higher numbers of pre-period severe relapse (p < 0.001). Lower MPR across the duration of the post period (p < 0.001) and patients enrolled in independent or preferred provider organization (p < 0.001) more likely to experience a severe relapse in the post-period. CONCLUSIONS: Comparative Effectiveness Research (CER) is an important tool that can be beneficial to inform the design and implementation of outcome based contracting between health plans and pharmaceutical manufacturers.

NEUROLOGICAL DISORDERS – Research on Methods

PND60
IDENTIFYING A CONDITION WITH NO ICD-9-CM DIAGNOSIS CODE FROM ADMINISTRATIVE CLAIMS DATA: POST-STROKE PATIENTS WITH PSEUDOBULBAR AFFECT
Halpern FN1, Yuan Y2, Chen S2, Dodell M3
1OptumInsight, Eden Prairie, MN, USA; 2Avanir Pharmaceuticals, Inc., Grass Valley, CA, USA
OBJECTIVES: Pseudobulbar affect (PBA) is a neurological condition characterized by uncontrolled outbursts of laughter or crying. It occurs secondary to brain injury or neurologic disease. PBA is often confused with other mental health (MH) conditions, and is challenging to identify retrospectively with claims data because an ICD-9-CM diagnosis code was not designated until late 2011. PBA is often treated with antidepressants, anticonvulsants, antipsychotics, or anxiolytics. Estimated prevalence of PBA secondary to stroke is 7% to 50%. Our study objective was to identify PBA in a population of post-stroke patients. METHODS: Commercial and Medicare Advantage members with incident stroke from January 1, 2007 to February 28, 2010 were identified with retrospective claims data from a large US health plan. Patients were continuously enrolled for 12 months pre- and post-stroke. Those with stroke care, MH conditions (depression, bipolar, generalized anxiety or personality disorders), antidepressants, or diagnoses of emotional lability (ICD-9 799.24, 310.8x) pre-stroke were excluded. Post-stroke PBA was identified with ICD-9 codes for emotional lability, ≤1 MH-related ambulatory visit, or ≤1 claim for a serotonergic reuptake inhibitor (SNRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) plus ≤1 claim for anticonvulant, antipsychotic, or anxiolytic within 6 months post-stroke. Sensitivity of the criteria was tested by requiring more medication claims or adding MH-related hospitalization. RESULTS: The study population comprised 9408 post-stroke patients. The PBA criteria identified 605 (10.3%) of commercial and 253 (7.1%) of Medicare Advantage subjects. Less than 1% had diagnoses indicating emotional lability. Stricter medication criteria reduced the PBA cohort ≤2 percentage points, indicating most patients had multiple SNRI and other medication fills. MH-related hospitalizations increased the PBA cohort <1 percentage point. Overall, 8.6-11.1% of commercial and 6.6-7.9% of Medicare Advantage patients had potential PBA, depending on criteria. CONCLUSIONS: The criteria identified a stable potential PBA cohort within the range of estimated PBA prevalence.

URINARY/KIDNEY DISORDERS – Clinical Outcomes Studies

PUK1
THE EFFECT OF COADMINISTRATION OF NICOTINAMIDE AND CALCIUM-BASED PHOSPHATE BINDER ON HYPERPHOSPHATEMIA IN PATIENTS UNDERGOING HEMODIALYSIS
Allan S1, E1Hamamy M2, E1Sharkawy M2
1Min International University, Cairo, Egypt; 2 Ain Shams University, Cairo, Egypt
OBJECTIVES: Assessment the safety and the efficacy of nicotinamide as adjunctive therapy to calcium carbonate (phosphate binder). METHODS: Study design and setting: A prospective, interventional, open-labeled, case control randomized trial was performed at Ain Shams University Specialized Hospital and AI Matomayz hemodialysis center, Cairo, Egypt, from August 2010 to December 2010. RESULTS AND METHODS: SIXTY ALCHD PATIENTS: Median phosphorus levels ≥5.0 mg/dl were classified into two groups, group I (control group) in which patients received calcium carbonate tablets in dose of 500mg to 1000mg three t.i.d. and group II (study group) in which patients received calcium carbonate in dose of 500mg to 1000mg t.i.d. and nicotinamide tablets in a dose tiritated to 1000mg/day for 8 weeks. Serum calcium, phosphorus and intact parathyroid hormone were measured at week 1 and 9 to assess the efficacy of treatment. RESULTS: Fifty-six patients successfully completed the trial. Serum phosphorus level falls significantly from 6.75 to 5.47 mg/dl with group II and not with group I (from 6.46 to 6.53 mg/dl). A concurrent fall in calcium: phosphorus product was seen with nicotinamide treatment (from 58.7 to 48.55 mg2/dl2), whereas serum calcium, intact parathyroid hormone, uric acid, platelet count, total cholesterol, hemoglobin, AST, and ALT remained stable in both arms. A trend increasing during HDL and reducing LDL and triglycerides were reported in nicotinamide group however the overall changes were statistically non significant. Diarrhea and other gastrointestinal disturbances symptoms were the major adverse effects seen with nicotinamide treatment. CONCLUSIONS: Nicotinamide in single dose of 1000 mg day can effectively reduce serum phosphorus when administered with calcium carbonate (phosphate binder) with less potential side effects.

PUK2
ODDS OF MISSED HEMODIALYSIS SESSIONS ARE INCREASED DURING HOLIDAY PERIODS AMONG IN-CENTER HEMODIALYSIS PATIENTS
Crawford SD1, Wang X2, Obarra PC, Sibbel SF
1Minnesota Medical Research, Minneapolis, MN, USA; 2A10801A
OBJECTIVES: Missed dialysis sessions place a significant economic burden on dialysis facilities, compromising dialysis delivery and increasing the cost of hemodialysis. Longer interdialytic intervals have been shown to increase morbidity and mortality and may result in increased time on dialysis. We therefore assessed the likelihood of missed dialysis sessions during holiday periods, which may prolong interdialytic intervals. METHODS: We evaluated missed sessions during holiday and non-holiday periods among 2474 in-center hemodialysis patients from 2006-2010. We assessed 5 holidays (Memorial day, Independence day, Labor day, Thanksgiving, and Christmas/New Year) and compared the proportion of missed sessions in the week surrounding the holiday relative to non-holiday periods. A 3-week interval was utilized for Christmas/New Years. Generalized binomial models were fit over time and adjusted for potential confounders including age, race, gender, dialysis vintage and vascular access. RESULTS: From 2006-2009, we observed a higher proportion of missed sessions over Thanksgiving and Christmas. In particular, Christmas was associated with a 5.8-fold (0.218 vs. 0.038, p<0.0001) and 3.7-fold (0.241 vs 0.065, p<0.0001) higher proportion compared to the non-holiday periods in January and July respectively. Conversely, missed sessions during Memorial Day, Independence Day, and Labor Day did not differ from non-holidays. Thanksgiving (OR: 1.21, 95% CI 1.10, 1.32) and Christmas (OR: 3.88, 95% CI 3.68, 4.09) were both associated with a higher odds of missed sessions, even after adjusting for confounders. CONCLUSIONS: Missed dialysis sessions during Christmas and Christmas travel periods were associated with a higher likelihood of missed dialysis sessions. Increased travel away from dialysis facilities, overeating, and higher fluid intake may all contribute, suggesting a continued need for vigilant patient communication during holidays to help mitigate the economic and adverse impact of missed dialysis sessions. Further research should verify the association in larger samples and assess the economic impact of missed hemodialysis sessions.